Last updated: August 2, 2026
Riociguat, marketed by Bayer as Adempas, is a differentiated soluble guanylate cyclase stimulator approved for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Its commercial trajectory has been stronger than the size of the pulmonary hypertension market would suggest, supported by orphan-drug positioning, limited competition in inoperable or persistent CTEPH, and chronic treatment duration.
Bayer’s Adempas revenue has grown from a launch-stage product into a roughly €1 billion annual franchise. The principal risks are a maturing PAH market, competition from combination regimens and sotatercept, loss of exclusivity from small-molecule generics, and payer pressure on chronic specialty medicines. Biosimilar risk does not apply because riociguat is a chemically synthesized small molecule rather than a biologic.
What is riociguat and which diseases does it treat?
Riociguat directly stimulates soluble guanylate cyclase and increases sensitivity to endogenous nitric oxide. The mechanism improves cyclic guanosine monophosphate signaling, producing pulmonary vasodilation and reducing pulmonary vascular resistance.
The FDA approved Adempas in October 2013 for two indications:
| Indication |
Patient population |
Commercial relevance |
| Chronic thromboembolic pulmonary hypertension |
Persistent or recurrent CTEPH after surgical treatment, or inoperable CTEPH |
Riociguat has a particularly strong position because medical alternatives are limited |
| Pulmonary arterial hypertension |
Adults with WHO Group 1 PAH |
Competes with endothelin-receptor antagonists, PDE5 inhibitors and prostacyclin therapies |
The CTEPH indication is the strategic anchor. Patients with operable disease generally undergo pulmonary endarterectomy, while balloon pulmonary angioplasty is used in selected patients. Riociguat is used when surgery is not appropriate or when pulmonary hypertension persists after surgery. The PAH indication is larger but more competitive. The FDA label prohibits coadministration with PDE5 inhibitors and nitrates because of hypotension risk. (FDA, 2024a)
How large is the riociguat market?
Riociguat is part of the broader pulmonary hypertension market, which includes branded and generic oral therapies, inhaled and parenteral prostacyclins, and newer biologic or biologic-like treatments.
The addressable market is shaped by several factors:
- PAH is a chronic, high-cost specialty disease with long treatment duration.
- CTEPH diagnosis remains difficult, limiting the treated population.
- Treatment is increasingly based on early combination therapy.
- Patients frequently move between or combine mechanisms over time.
- Specialty pharmacies and pulmonary hypertension centers influence prescribing.
- The treatment population is concentrated in North America, Western Europe and Japan.
Riociguat’s direct market is smaller than the overall PAH market but has a defensible niche in CTEPH. Its principal commercial advantages are an approved CTEPH indication, guideline recognition and clinical data from the CHEST and PATENT programs. (Ghofrani et al., 2013a; Ghofrani et al., 2013b)
How does riociguat compare with competing pulmonary hypertension drugs?
| Product or class |
Representative products |
Main advantage |
Competitive effect on riociguat |
| Soluble guanylate cyclase stimulator |
Riociguat |
Approved in PAH and CTEPH |
Owns the class, but has no same-class branded competitor |
| PDE5 inhibitors |
Sildenafil, tadalafil |
Low cost, broad familiarity, generic availability |
Strong price and prescribing pressure in PAH |
| Endothelin-receptor antagonists |
Macitentan, ambrisentan, bosentan |
Established PAH use and combination therapy |
Compete for first-line and add-on treatment |
| Prostacyclin pathway drugs |
Treprostinil, epoprostenol, selexipag |
Strong efficacy in advanced disease |
More relevant in high-risk or progressive PAH |
| Activin-signaling inhibitor |
Sotatercept, Winrevair |
New mechanism and significant clinical efficacy |
Could reduce riociguat use in advanced or combination-treated PAH |
| Surgical or interventional treatment |
Pulmonary endarterectomy, balloon pulmonary angioplasty |
Potentially definitive for selected CTEPH patients |
Limits riociguat use in operable CTEPH |
Sotatercept is the most important recent competitive development. The FDA approved Winrevair in March 2024 for adults with PAH to increase exercise capacity and improve functional status. It is administered by subcutaneous injection and can be added to background therapy. The drug could pressure oral PAH therapies, although its effect on riociguat depends on sequencing, reimbursement and long-term treatment practice. (FDA, 2024b)
What has been riociguat’s financial trajectory?
Bayer reports Adempas sales within its Pharmaceuticals division. The product has shown sustained growth since launch, helped by increasing recognition of CTEPH and continued use in PAH.
| Fiscal year |
Approximate Bayer Adempas sales |
Commercial interpretation |
| 2014 |
€0.2 billion |
Early launch period |
| 2016 |
€0.5 billion |
Expansion in PAH and CTEPH |
| 2018 |
€0.7 billion |
Broader specialist adoption |
| 2020 |
€0.8-0.9 billion |
Resilient specialty demand despite the pandemic |
| 2021 |
Approximately €0.9 billion |
Continued volume growth |
| 2022 |
Approximately €1.0 billion |
Franchise reached blockbuster scale |
| 2023 |
Approximately €1.0 billion |
Mature but durable revenue base |
| 2024 |
Approximately €1.0 billion |
Growth increasingly dependent on retention and pricing |
The figures are Bayer-reported product sales in euros, rounded from annual-report disclosures. They should not be compared directly with U.S. net sales because Bayer’s figures include global sales and reflect currency movements. (Bayer AG, 2021, 2022, 2023, 2024)
Why has Adempas reached blockbuster-scale revenue?
The product’s financial performance reflects four structural factors.
First, riociguat treats two rare diseases with chronic therapy requirements. Second, the CTEPH indication has fewer pharmacologic substitutes than PAH. Third, treatment is concentrated in specialist centers that can support high-cost reimbursement. Fourth, the product has no approved direct generic competitor in the early post-launch period covered by Bayer’s strongest growth years.
The revenue base is more durable than a single-indication PAH product, but it is not immune to erosion. Generic PDE5 inhibitors already create a low-cost alternative in PAH, while sotatercept introduces a new premium competitor. Bayer’s longer-term sales growth therefore depends more on CTEPH retention, treatment-line positioning and geographic expansion than on broad new-patient growth.
When does riociguat lose exclusivity?
Riociguat’s exclusivity does not end on a single date. Regulatory exclusivity, compound patents, formulation patents and method-of-use patents create separate barriers.
Regulatory exclusivity
The original U.S. approvals received orphan-drug exclusivity. The CTEPH approval received seven years of orphan exclusivity from the 2013 approval, while the PAH approval received a separate orphan period associated with the approved indication. Those regulatory periods have expired.
Orphan exclusivity prevents FDA approval of the same drug for the same disease or condition during the statutory period. It does not prevent all patent challenges, off-label use or approval of a different product for another indication. (FDA, 2024c)
Riociguat is not a biologic. There is no reference-product exclusivity or biosimilar pathway comparable to products regulated under the Public Health Service Act. Any future competitor would generally use an abbreviated new drug application, subject to pharmaceutical-equivalence, bioequivalence and patent-certification requirements.
Patent exclusivity
The riociguat patent estate includes several categories:
| Patent category |
Protection target |
Expected commercial role |
| Core chemical compound |
Riociguat and related pyrazolopyridine compounds |
Earlier foundational protection |
| Pharmaceutical composition |
Tablet compositions and dosage forms |
Can extend protection beyond the core compound |
| Dosage regimen |
Dose titration and administration methods |
Relevant to labeling and infringement strategy |
| Method of treatment |
PAH and CTEPH treatment methods |
May create later-expiring barriers |
| Manufacturing and solid-state properties |
Crystalline forms, processes and intermediates |
Can complicate generic development |
The original compound protection is closer to expiration than later formulation and use claims. Public patent databases identify U.S. riociguat patents with expiration dates extending into the late 2020s and, for some later-filed claims, the early 2030s. The practical launch date depends on which listed claims survive challenge, patent-term adjustment, pediatric extensions and any settlement with an ANDA applicant. FDA Orange Book entries and the relevant patent records are the controlling sources for a launch analysis. (FDA, 2024d; USPTO, 2024)
What is the Orange Book status of Adempas?
Adempas is listed in the FDA Orange Book as a prescription product containing riociguat in oral tablet strengths. The listed dosage strengths include 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg tablets.
The Orange Book is relevant for three reasons:
- It identifies approved strengths and dosage forms.
- It identifies patents submitted by the NDA holder.
- It provides the framework for generic applicants to make Paragraph I, II, III or IV certifications.
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. Bayer can sue within the statutory period after receiving notice, triggering an automatic stay of approval for up to 30 months unless the litigation is resolved earlier. (FDA, 2024d)
What formulations are protected by riociguat patents?
The commercial product is an immediate-release oral tablet. The patent estate is therefore more likely to focus on tablet composition, dosing, treatment methods and manufacturing than on complex delivery technology.
This is a favorable profile for generic developers compared with an extended-release, inhaled or injectable product. A generic manufacturer can potentially reproduce the immediate-release dosage form through conventional oral-solid-dose manufacturing. The main barriers are patent claims, bioequivalence requirements, stability, impurity controls and the need to match multiple strengths.
Which companies are challenging Adempas patents?
Generic companies commonly target successful oral specialty medicines after the core compound patent approaches expiration. A Paragraph IV strategy for riociguat would likely focus on:
- Invalidity of later formulation claims.
- Non-infringement of method-of-use claims.
- Carve-outs for protected indications.
- Challenges to dosage-regimen claims.
- Limited initial launches directed to nonprotected uses.
Publicly available sources cited here do not establish a completed generic launch or a final, market-clearing judgment involving a specific riociguat ANDA applicant. The relevant risk is therefore prospective rather than a demonstrated current erosion event. FDA approval records, Orange Book updates and federal court dockets remain the decisive evidence for identifying an active challenger.
What generic entry risks exist for riociguat?
Riociguat has a medium-to-high long-term generic risk and a lower near-term risk.
Near-term risk
Near-term risk is moderated by:
- Multiple patent categories.
- High regulatory and commercial specialization.
- The need to support several tablet strengths.
- A concentrated prescriber base.
- Potential litigation over use and formulation claims.
Post-exclusivity risk
Once a first generic launches, erosion could be substantial because riociguat is an oral small molecule. The product does not have the manufacturing complexity of an injectable prostacyclin or biologic. Generic entry could produce rapid price discounting, particularly in PAH where sildenafil and tadalafil already establish low-cost treatment expectations.
CTEPH may be more resilient because treatment is concentrated in specialist centers and the therapeutic alternatives are less interchangeable. Still, a generic would likely pressure both U.S. and European prices over time.
How strong is the riociguat patent estate?
The patent estate is commercially meaningful but not impenetrable.
Its strengths are:
- Multiple protection categories rather than reliance on only one compound patent.
- Two approved indications.
- A clinically differentiated mechanism.
- Method-of-use claims tied to specialist treatment pathways.
- Potentially later-expiring patents covering formulations or administration.
Its weaknesses are:
- Riociguat is a small molecule with conventional oral tablets.
- Core regulatory exclusivity has expired.
- Generic companies can use Paragraph IV litigation.
- PAH treatment contains established generic alternatives.
- Method-of-use claims may be narrowed through label carve-outs.
- CTEPH and PAH claims can be attacked separately.
The estate is stronger as a portfolio than as a single blocking right. Commercial protection after the foundational patent period depends on the validity and enforceability of later patents and on whether a generic applicant can launch with a restricted label.
What patent litigation and settlement issues affect riociguat?
The principal litigation risk is ANDA litigation under the Hatch-Waxman framework. A generic applicant that certifies Paragraph IV can trigger a patent case in federal court. The case may address compound, formulation, dosage or method-of-use claims.
A settlement could establish:
- An agreed generic launch date.
- A license before patent expiry.
- Restrictions on product strengths or indications.
- A nonexclusive or exclusive supply arrangement.
- A contingent launch tied to court outcomes.
No settlement should be assumed without a filed agreement, court docket or regulatory disclosure. Bayer’s annual reports describe material litigation and business risks at the company level but do not establish a universal riociguat settlement date. (Bayer AG, 2024)
What licensing deals are associated with riociguat?
Riociguat was discovered and developed by Bayer. Bayer has retained the central commercial and regulatory role for Adempas, while its broader pharmaceutical history includes regional collaborations and commercialization arrangements.
The material commercial question is not a traditional external license comparable to a biotech-originated asset. It is the allocation of rights, development responsibilities and sales economics between Bayer and regional partners. Any regional co-promotion or commercialization rights can affect reported revenue, but Bayer’s consolidated sales disclosures remain the best measure of franchise performance.
What is the FDA regulatory status of riociguat?
Riociguat has full FDA approval for adult CTEPH and PAH uses. The product is not an investigational therapy and does not depend on accelerated approval. The major regulatory constraints are clinical and labeling-related:
- Do not use with PDE5 inhibitors.
- Avoid concurrent nitrate therapy.
- Pregnancy is contraindicated because of embryo-fetal toxicity.
- Women of reproductive potential require pregnancy testing and risk-management controls.
- Dose titration is required to reduce hypotension risk.
The FDA’s risk-management requirements increase prescribing complexity but also reinforce specialist-channel control. (FDA, 2024a)
How will sotatercept affect riociguat revenue?
Sotatercept is likely to affect riociguat first in PAH patients with inadequate control on background therapy. Its impact will depend on whether clinicians use it as an add-on treatment or substitute it for existing oral agents.
The likely competitive pattern is segmented:
| Patient segment |
Likely riociguat exposure |
| Inoperable or persistent CTEPH |
Relatively protected |
| Newly diagnosed PAH |
Vulnerable to treatment-algorithm changes |
| PAH on multiple oral therapies |
Vulnerable to sotatercept add-on use |
| Advanced PAH requiring prostacyclin therapy |
Competition depends on severity and route preference |
| Patients stabilized on riociguat |
More resistant to immediate switching |
Sotatercept does not directly replace riociguat in CTEPH because its FDA indication is PAH. That distinction protects the most differentiated portion of Adempas demand.
What is the geographic exposure of the riociguat franchise?
North America and Europe are the principal commercial regions for high-cost pulmonary hypertension therapy. Japan and other developed markets add meaningful but smaller revenue pools. Market access differs by jurisdiction:
- The United States relies on specialty pharmacy distribution, prior authorization and pulmonary hypertension centers.
- Europe uses national and regional reimbursement assessments, creating price variation.
- Japan has a specialized pulmonary hypertension treatment base and distinct reimbursement rules.
- Emerging markets have lower access because of diagnosis, reimbursement and specialist infrastructure constraints.
Currency translation can materially affect Bayer’s euro-reported sales. A stable prescription base can produce different reported growth rates depending on exchange rates and regional pricing.
What is the generic launch scenario for Adempas?
The most likely launch sequence is:
- Paragraph IV filings as later patent dates approach.
- Bayer litigation or negotiated settlements.
- Possible first-to-file exclusivity for an eligible generic applicant.
- Initial limited competition.
- Rapid price erosion after multiple generic entrants.
The commercial value of an early generic launch would depend on whether the entrant can market all strengths and both disease indications. A carve-out excluding CTEPH could produce a partial launch, preserving some branded revenue. A full-label launch after the relevant patents expire would create the largest revenue shock.
Key Takeaways
- Riociguat is Bayer’s Adempas, an oral soluble guanylate cyclase stimulator for PAH and CTEPH.
- CTEPH gives the product a more defensible market position than PAH alone.
- Adempas has developed into an approximately €1 billion annual global franchise.
- Regulatory exclusivity has expired, but patent protection may extend into the late 2020s and, for selected later claims, the early 2030s.
- Riociguat is a small molecule, so biosimilar risk does not apply.
- Generic risk is lower before a successful Paragraph IV challenge and high after full-label generic entry.
- Sotatercept is the most important new competitive threat in PAH, but it does not currently cover CTEPH.
- The key diligence items are Orange Book patent listings, ANDA notices, Paragraph IV complaints, patent-term adjustments and settlement terms.
FAQs
Is riociguat a biologic or a small-molecule drug?
Riociguat is a chemically synthesized small molecule. Future competitors would generally pursue an ANDA rather than a biosimilar application.
Is riociguat approved for chronic thromboembolic pulmonary hypertension?
Yes. FDA approval covers adults with inoperable CTEPH or persistent or recurrent CTEPH after surgical treatment.
Can riociguat be taken with sildenafil or tadalafil?
No. The FDA label contraindicates concurrent use with PDE5 inhibitors because of the risk of excessive blood-pressure reduction.
Does sotatercept replace riociguat?
Not universally. Sotatercept is approved for PAH, while riociguat also has a CTEPH indication. Treatment decisions depend on disease type, severity, prior therapy and specialist judgment.
What is the main investment risk for Bayer’s Adempas revenue?
The main risk is loss of small-molecule exclusivity followed by generic price erosion. In PAH, competitive pressure from sotatercept and low-cost PDE5 inhibitors creates an earlier commercial risk than in CTEPH.
References
-
Bayer AG. (2021). Annual report 2021. Bayer AG.
-
Bayer AG. (2022). Annual report 2022. Bayer AG.
-
Bayer AG. (2023). Annual report 2023. Bayer AG.
-
Bayer AG. (2024). Annual report 2024. Bayer AG.
-
Ghofrani, H. A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., Neuser, D., Weimann, G., Wang, C., & CHEST-1 Study Group. (2013a). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine, 369(4), 319-329.
-
Ghofrani, H. A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z. C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., Neuser, D., Rubin, L. J., & PATENT-1 Study Group. (2013b). Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine, 369(4), 330-340.
-
U.S. Food and Drug Administration. (2024a). Adempas prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024b). FDA approves drug to treat adults with pulmonary arterial hypertension. FDA.
-
U.S. Food and Drug Administration. (2024c). Orphan drug designation and exclusivity. FDA.
-
U.S. Food and Drug Administration. (2024d). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment records. USPTO.
